AMICUS THERAPEUTICS INC (FOLD) Stock Fundamental Analysis
NASDAQ:FOLD - US03152W1099 - Common Stock
8.02 USD
+0.17 (+2.17%)
8.02 USD
0 (0%)
Taking everything into account, FOLD scores 4 out of 10 in our fundamental rating. FOLD was compared to 542 industry peers in the Biotechnology industry. While FOLD is still in line with the averages on profitability rating, there are concerns on its financial health. FOLD has a decent growth rate and is not valued too expensively.
1. Profitability
1.1 Basic Checks
In the past year FOLD has reported negative net income.
In the past year FOLD has reported a negative cash flow from operations.
In the past 5 years FOLD always reported negative net income.
FOLD had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
The Return On Assets of FOLD (-4.67%) is better than 87.45% of its industry peers.
FOLD has a better Return On Equity (-18.65%) than 85.98% of its industry peers.
FOLD has a Return On Invested Capital of 3.06%. This is amongst the best in the industry. FOLD outperforms 90.96% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -4.67% | ||
| ROE | -18.65% | ||
| ROIC | 3.06% |
ROA(3y)-19.77%
ROA(5y)-23.64%
ROE(3y)-105.3%
ROE(5y)-98.82%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
FOLD has a better Operating Margin (4.39%) than 90.41% of its industry peers.
The Gross Margin of FOLD (90.37%) is better than 91.88% of its industry peers.
In the last couple of years the Gross Margin of FOLD has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 4.39% | ||
| PM (TTM) | N/A | ||
| GM | 90.37% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.48%
GM growth 5Y0.45%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so FOLD is destroying value.
FOLD has more shares outstanding than it did 1 year ago.
The number of shares outstanding for FOLD has been increased compared to 5 years ago.
FOLD has a better debt/assets ratio than last year.
2.2 Solvency
FOLD has an Altman-Z score of -1.06. This is a bad value and indicates that FOLD is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -1.06, FOLD is in line with its industry, outperforming 57.38% of the companies in the same industry.
FOLD has a Debt/Equity ratio of 1.92. This is a high value indicating a heavy dependency on external financing.
FOLD's Debt to Equity ratio of 1.92 is on the low side compared to the rest of the industry. FOLD is outperformed by 80.26% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.92 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -1.06 |
ROIC/WACC0.28
WACC10.75%
2.3 Liquidity
FOLD has a Current Ratio of 3.21. This indicates that FOLD is financially healthy and has no problem in meeting its short term obligations.
With a Current ratio value of 3.21, FOLD is not doing good in the industry: 61.62% of the companies in the same industry are doing better.
FOLD has a Quick Ratio of 2.29. This indicates that FOLD is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 2.29, FOLD is doing worse than 69.19% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.21 | ||
| Quick Ratio | 2.29 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 71.79% over the past year.
FOLD shows a strong growth in Revenue. In the last year, the Revenue has grown by 25.35%.
FOLD shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 23.73% yearly.
EPS 1Y (TTM)71.79%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-40%
Revenue 1Y (TTM)25.35%
Revenue growth 3Y20.03%
Revenue growth 5Y23.73%
Sales Q2Q%22.12%
3.2 Future
Based on estimates for the next years, FOLD will show a very strong growth in Earnings Per Share. The EPS will grow by 70.90% on average per year.
FOLD is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 19.28% yearly.
EPS Next Y67.89%
EPS Next 2Y89.72%
EPS Next 3Y73.76%
EPS Next 5Y70.9%
Revenue Next Year18.91%
Revenue Next 2Y19.82%
Revenue Next 3Y19.71%
Revenue Next 5Y19.28%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for FOLD. In the last year negative earnings were reported.
The Price/Forward Earnings ratio is 27.86, which means the current valuation is very expensive for FOLD.
FOLD's Price/Forward Earnings ratio is rather cheap when compared to the industry. FOLD is cheaper than 91.51% of the companies in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 22.63, FOLD is valued a bit more expensive.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 27.86 |
4.2 Price Multiples
FOLD's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. FOLD is cheaper than 90.04% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 76.11 |
4.3 Compensation for Growth
FOLD's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
FOLD's earnings are expected to grow with 73.76% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y89.72%
EPS Next 3Y73.76%
5. Dividend
5.1 Amount
No dividends for FOLD!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
8.02
+0.17 (+2.17%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners95.61%
Inst Owner Change1.1%
Ins Owners0.6%
Ins Owner Change2.43%
Market Cap2.47B
Analysts83.33
Price Target16.22 (102.24%)
Short Float %7.25%
Short Ratio4.77
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)7.84%
Min EPS beat(2)-26.06%
Max EPS beat(2)41.73%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-3.25%
Min Revenue beat(2)-9.62%
Max Revenue beat(2)3.12%
Revenue beat(4)2
Avg Revenue beat(4)-1.2%
Min Revenue beat(4)-9.62%
Max Revenue beat(4)3.12%
Revenue beat(8)4
Avg Revenue beat(8)-0.78%
Revenue beat(12)7
Avg Revenue beat(12)-0.51%
Revenue beat(16)8
Avg Revenue beat(16)-1.25%
PT rev (1m)1.49%
PT rev (3m)0.63%
EPS NQ rev (1m)60.74%
EPS NQ rev (3m)53.44%
EPS NY rev (1m)35.44%
EPS NY rev (3m)23.87%
Revenue NQ rev (1m)0.52%
Revenue NQ rev (3m)0.47%
Revenue NY rev (1m)0.85%
Revenue NY rev (3m)0.94%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 27.86 | ||
| P/S | 4.33 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 12.1 | ||
| P/tB | N/A | ||
| EV/EBITDA | 76.11 |
EPS(TTM)-0.11
EYN/A
EPS(NY)0.29
Fwd EY3.59%
FCF(TTM)-0.16
FCFYN/A
OCF(TTM)-0.15
OCFYN/A
SpS1.85
BVpS0.66
TBVpS-0.03
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -4.67% | ||
| ROE | -18.65% | ||
| ROCE | 3.87% | ||
| ROIC | 3.06% | ||
| ROICexc | 4.75% | ||
| ROICexgc | 9.73% | ||
| OM | 4.39% | ||
| PM (TTM) | N/A | ||
| GM | 90.37% | ||
| FCFM | N/A |
ROA(3y)-19.77%
ROA(5y)-23.64%
ROE(3y)-105.3%
ROE(5y)-98.82%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.48%
GM growth 5Y0.45%
F-Score5
Asset Turnover0.7
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.92 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 11.88 | ||
| Cap/Depr | 41.25% | ||
| Cap/Sales | 0.57% | ||
| Interest Coverage | 0.44 | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 3.21 | ||
| Quick Ratio | 2.29 | ||
| Altman-Z | -1.06 |
F-Score5
WACC10.75%
ROIC/WACC0.28
Cap/Depr(3y)68.89%
Cap/Depr(5y)61.13%
Cap/Sales(3y)1.23%
Cap/Sales(5y)1.24%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)71.79%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-40%
EPS Next Y67.89%
EPS Next 2Y89.72%
EPS Next 3Y73.76%
EPS Next 5Y70.9%
Revenue 1Y (TTM)25.35%
Revenue growth 3Y20.03%
Revenue growth 5Y23.73%
Sales Q2Q%22.12%
Revenue Next Year18.91%
Revenue Next 2Y19.82%
Revenue Next 3Y19.71%
Revenue Next 5Y19.28%
EBIT growth 1Y191.42%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year134.62%
EBIT Next 3Y105.52%
EBIT Next 5YN/A
FCF growth 1Y63.3%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y63.94%
OCF growth 3YN/A
OCF growth 5YN/A